Enanta Pharmaceuticals (US.ENTA)
资本配置审计 · 期间： 2010 – 2026
核心指标
US.ENTA · 同比： 2026 H1 vs 2025 H1
| 指标 | 数值 | 同比 |
|---|---|---|
| FCF Conversion | 100.8% | ↓ |
| ROE | -21.5% | ↑ |
| Cash Conversion | - | → |
| D/E Ratio | 0.48 | ↑ |
| Gross Margin | 0.0% | ↓ |
US.ENTA (Enanta Pharmaceuticals) | YoY: 2026 H1 vs 2025 H1 Metric Value YoY ---------------------------- FCF Conversion 100.8% ↓ ROE -21.5% ↑ Cash Conversion - → D/E Ratio 0.48 ↑ Gross Margin 0.0% ↓
核心指标
US.ENTA (Enanta Pharmaceuticals) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY----------------------------FCF Conversion 100.8% ↓ROE -21.5% ↑Cash Conversion - →D/E Ratio 0.48 ↑Gross Margin 0.0% ↓免费公司
AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies